EE04914B1 - Eletriptaanvesinikbromiidi monohüdraat, selle kasutamine ja protsess selle valmistamiseks ning eletriptaanvesinikbromiidi monohüdraati sisaldav farmatseutiline kompositsioon - Google Patents

Eletriptaanvesinikbromiidi monohüdraat, selle kasutamine ja protsess selle valmistamiseks ning eletriptaanvesinikbromiidi monohüdraati sisaldav farmatseutiline kompositsioon

Info

Publication number
EE04914B1
EE04914B1 EEP200100285A EEP200100285A EE04914B1 EE 04914 B1 EE04914 B1 EE 04914B1 EE P200100285 A EEP200100285 A EE P200100285A EE P200100285 A EEP200100285 A EE P200100285A EE 04914 B1 EE04914 B1 EE 04914B1
Authority
EE
Estonia
Prior art keywords
eletriptan hydrobromide
hydrobromide monohydrate
preparation
pharmaceutical composition
composition containing
Prior art date
Application number
EEP200100285A
Other languages
English (en)
Estonian (et)
Inventor
Ian Dallman Christopher
James Ogilvie Ronald
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of EE200100285A publication Critical patent/EE200100285A/xx
Publication of EE04914B1 publication Critical patent/EE04914B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Electroluminescent Light Sources (AREA)
  • Lasers (AREA)
  • Indole Compounds (AREA)
EEP200100285A 1998-11-27 1999-11-01 Eletriptaanvesinikbromiidi monohüdraat, selle kasutamine ja protsess selle valmistamiseks ning eletriptaanvesinikbromiidi monohüdraati sisaldav farmatseutiline kompositsioon EE04914B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9825988.0A GB9825988D0 (en) 1998-11-27 1998-11-27 Indole derivatives
PCT/IB1999/001754 WO2000032589A1 (en) 1998-11-27 1999-11-01 Eletriptan hydrobromide monohydrate

Publications (2)

Publication Number Publication Date
EE200100285A EE200100285A (et) 2002-08-15
EE04914B1 true EE04914B1 (et) 2007-10-15

Family

ID=10843140

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100285A EE04914B1 (et) 1998-11-27 1999-11-01 Eletriptaanvesinikbromiidi monohüdraat, selle kasutamine ja protsess selle valmistamiseks ning eletriptaanvesinikbromiidi monohüdraati sisaldav farmatseutiline kompositsioon

Country Status (53)

Country Link
US (2) US20020013358A1 (uk)
EP (1) EP1135381B1 (uk)
JP (1) JP3777094B2 (uk)
KR (1) KR100413739B1 (uk)
CN (1) CN1131860C (uk)
AP (1) AP2001002149A0 (uk)
AR (1) AR024232A1 (uk)
AT (1) ATE273300T1 (uk)
AU (1) AU754731B2 (uk)
BG (1) BG64706B1 (uk)
BR (1) BR9915692A (uk)
CA (1) CA2352392C (uk)
CO (1) CO5150178A1 (uk)
CR (1) CR6325A (uk)
CU (1) CU23269A3 (uk)
CZ (1) CZ295472B6 (uk)
DE (1) DE69919388T2 (uk)
DK (1) DK1135381T3 (uk)
DZ (1) DZ2948A1 (uk)
EA (1) EA003551B1 (uk)
EE (1) EE04914B1 (uk)
ES (1) ES2224701T3 (uk)
GB (1) GB9825988D0 (uk)
GC (1) GC0000113A (uk)
GE (1) GEP20043183B (uk)
GT (1) GT199900202A (uk)
HK (1) HK1042898B (uk)
HN (1) HN1999000196A (uk)
HR (1) HRP20010398B1 (uk)
HU (1) HUP0105308A3 (uk)
ID (1) ID28802A (uk)
IL (1) IL141663A (uk)
IS (1) IS2238B (uk)
MA (1) MA26708A1 (uk)
MY (1) MY124078A (uk)
NO (1) NO320798B1 (uk)
NZ (1) NZ510055A (uk)
OA (1) OA11671A (uk)
PA (1) PA8485701A1 (uk)
PE (1) PE20001299A1 (uk)
PL (1) PL194503B1 (uk)
PT (1) PT1135381E (uk)
RS (1) RS50002B (uk)
SI (1) SI1135381T1 (uk)
SK (1) SK285774B6 (uk)
SV (1) SV1999000204A (uk)
TN (1) TNSN99221A1 (uk)
TR (1) TR200101493T2 (uk)
TW (1) TWI246512B (uk)
UA (1) UA68402C2 (uk)
UY (2) UY25823A1 (uk)
WO (1) WO2000032589A1 (uk)
ZA (1) ZA200102681B (uk)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0018968D0 (en) * 2000-08-02 2000-09-20 Pfizer Ltd Particulate composition
WO2004089365A1 (en) 2003-04-11 2004-10-21 Pfizer Limited Pharmaceutical combination comprising eletriptan and sodium bicarbonate
US6927296B2 (en) 2003-07-23 2005-08-09 Pfizer Inc. Process
GB0317229D0 (en) * 2003-07-23 2003-08-27 Pfizer Ltd Improved process
EP2093225A1 (en) 2007-05-01 2009-08-26 Plus Chemicals B.V. Process for preparing crystalline eletriptan hydrobromide form ß
WO2008150500A1 (en) * 2007-05-29 2008-12-11 Plus Chemicals, S.A. A process for preparing 5-bromo-3-[(r)-1-methyl-pyrrolidin-2-ylmethyl]-1h-indole
WO2009077858A2 (en) * 2007-12-17 2009-06-25 Actavis Group Ptc Ehf Novel hemioxalate salt of eletriptan
US20120027816A1 (en) * 2009-02-25 2012-02-02 Actavis Group Ptc Ehf Highly pure eletriptan or a pharmaceutically acceptable salt thereof substantially free of eletriptan n-oxide impurity
WO2010116386A2 (en) * 2009-04-08 2010-10-14 Biophore India Pharmaceuticals Pvt. Ltd. Novel polymorph of eletriptan hydrobromide and process for the preparation thereof
US8754239B2 (en) 2010-01-19 2014-06-17 Sms Pharmaceuticals Limited Process for preparing eletriptan hydrobromide having α-form
WO2014063752A1 (en) 2012-10-26 2014-05-01 Synthon Bv Process for making crystalline form alpha of eletriptan hydrobromide
CN103893112A (zh) * 2012-12-31 2014-07-02 重庆圣华曦药业股份有限公司 氢溴酸依来曲普坦注射液
CN107954947A (zh) * 2016-10-14 2018-04-24 北京莱瑞森医药科技有限公司 沃替西汀氢溴酸盐晶型c及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3952741A (en) 1975-01-09 1976-04-27 Bend Research Inc. Controlled release delivery system by an osmotic bursting mechanism
FR2624732B1 (fr) 1987-12-21 1991-02-15 Synthelabo Formulation pharmaceutique a liberation prolongee
US5474784A (en) 1990-03-02 1995-12-12 British Technology Group Limited Dispensing device
RO111767B1 (ro) 1990-10-15 1997-01-30 Pfizer Derivati de indol, procedee si intermediari pentru prepararea acestora, compozitii farmaceutice si metoda pentru tratarea unor afectiuni
US5545644A (en) * 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
US5464633A (en) 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
GB9417310D0 (en) * 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
GB9510223D0 (en) 1995-05-20 1995-07-19 Pfizer Ltd Therapeutic agent
TW448172B (en) * 1996-03-08 2001-08-01 Pharmacia & Upjohn Co Llc Novel hydroxamic acid derivatives useful for the treatment of diseases related to connective tissue degradation
US5998462A (en) * 1996-12-16 1999-12-07 Allelix Biopharmaceuticals Inc. 5-alkyl indole compounds
GB9704498D0 (en) * 1997-03-05 1997-04-23 Glaxo Wellcome Spa Chemical compound
US6166025A (en) 1997-07-03 2000-12-26 Pfizer Inc. Pharmaceutical compositions containing eletriptran hemisulphate and caffeine

Also Published As

Publication number Publication date
HUP0105308A3 (en) 2003-01-28
HRP20010398B1 (en) 2004-12-31
ATE273300T1 (de) 2004-08-15
BG64706B1 (bg) 2005-12-30
HK1042898A1 (en) 2002-08-30
HUP0105308A2 (hu) 2002-05-29
IS5868A (is) 2001-02-27
SK6992001A3 (en) 2002-01-07
SV1999000204A (es) 2000-10-16
CU23269A3 (es) 2008-04-09
ES2224701T3 (es) 2005-03-01
EA003551B1 (ru) 2003-06-26
UY25825A1 (es) 2000-08-21
PE20001299A1 (es) 2000-12-01
GC0000113A (en) 2005-06-29
IL141663A0 (en) 2002-03-10
EP1135381A1 (en) 2001-09-26
MY124078A (en) 2006-06-30
BR9915692A (pt) 2001-08-14
RS50002B (sr) 2008-09-29
CR6325A (uk) 2008-07-02
OA11671A (en) 2005-01-12
AR024232A1 (es) 2002-09-25
UA68402C2 (en) 2004-08-16
YU18801A (sh) 2003-07-07
UY25823A1 (es) 2001-08-27
WO2000032589A1 (en) 2000-06-08
PL194503B1 (pl) 2007-06-29
PL347928A1 (en) 2002-04-22
GEP20043183B (en) 2004-02-25
GT199900202A (es) 2001-05-19
CZ20011839A3 (cs) 2001-10-17
TWI246512B (en) 2006-01-01
EE200100285A (et) 2002-08-15
CA2352392A1 (en) 2000-06-08
EP1135381B1 (en) 2004-08-11
PA8485701A1 (es) 2000-09-29
TNSN99221A1 (fr) 2005-11-10
EA200100297A1 (ru) 2001-08-27
SK285774B6 (sk) 2007-08-02
JP3777094B2 (ja) 2006-05-24
GB9825988D0 (en) 1999-01-20
CZ295472B6 (cs) 2005-08-17
KR100413739B1 (ko) 2004-01-03
MA26708A1 (fr) 2004-12-20
JP2002531449A (ja) 2002-09-24
US20020013358A1 (en) 2002-01-31
NO320798B1 (no) 2006-01-30
BG105539A (en) 2001-12-29
CN1328554A (zh) 2001-12-26
CN1131860C (zh) 2003-12-24
ZA200102681B (en) 2002-07-02
TR200101493T2 (tr) 2002-02-21
HN1999000196A (es) 2005-11-26
AP2001002149A0 (en) 2001-06-30
CA2352392C (en) 2006-01-24
SI1135381T1 (en) 2004-10-31
PT1135381E (pt) 2004-10-29
DK1135381T3 (da) 2004-11-15
HK1042898B (zh) 2004-10-08
IS2238B (is) 2007-05-15
KR20010080594A (ko) 2001-08-22
DE69919388T2 (de) 2005-09-29
AU754731B2 (en) 2002-11-21
NZ510055A (en) 2004-11-26
DE69919388D1 (de) 2004-09-16
ID28802A (id) 2001-07-05
DZ2948A1 (fr) 2004-03-15
IL141663A (en) 2004-05-12
CO5150178A1 (es) 2002-04-29
NO20012584D0 (no) 2001-05-25
HRP20010398A2 (en) 2002-06-30
US20050131237A1 (en) 2005-06-16
NO20012584L (no) 2001-07-27
AU6225399A (en) 2000-06-19
US7238723B2 (en) 2007-07-03

Similar Documents

Publication Publication Date Title
EE200000596A (et) Tienüülasolüülalkoksüetaanamiinderivaadid, nende ja nende soolade valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja kasutamine ning vaheühend ja selle valmistamismeetod
EE05214B1 (et) Polool-IFN- β konjugaat, selle valmistamismeetod ja farmatseutiline kompositsioon
EE200100318A (et) Kinoliini derivaat, selle ühendi kasutamine ravimina, seda sisaldav farmatseutiline kompositsioon ning meetod ühendi ja kompositsiooni valmistamiseks
EE200300171A (et) Kristalliline monohüdraat, meetodid selle valmistamiseks ja selle kasutamine farmatseutilise kompositsiooni valmistamiseks
EE200100252A (et) Pürimidiinderivaadid, nende valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja sellevalmistamismeetod, kombinatsioon ning saadus
HUP0203902A3 (en) Substituted oxazolidinones, process for their preparation and pharmaceutical compositions containing them and their use
HUP0103567A3 (en) 2-substituted-1-piperidyl benzimidazole compounds as orl1-receptor agonists, process for their preparation and pharmaceutical compositions containing the same
EE9800136A (et) Depooravimiks sobiv farmatseutiline kompositsioon, selle valmistamismeetod ja kasutamine
EE200200487A (et) Asetidiini derivaadid, nende valmistamismeetodid ja farmatseutiline kompositsioon
EE04464B1 (et) Indalüülasendatud benseenkarboksamiidid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
EE03338B1 (et) Tromboosivastane ravim, selle valmistamise protsess ja kasutamine
HUP0105313A3 (en) Potassium salt of (s)-omeprazole, process for its preparation and pharmaceutical composition containing the same and its use
EE9800302A (et) Arüülglütsiinamiidi derivaadid, nende valmistamismeetod ja kasutamine ning farmatseutiline preparaat
EE04490B1 (et) Ühend, selle valmistamise meetod ning kasutamine meditsiinis
HUP0203597A3 (en) Pharmaceutical compositions containing zolmitriptan, process for their preparation and their use
EE04914B1 (et) Eletriptaanvesinikbromiidi monohüdraat, selle kasutamine ja protsess selle valmistamiseks ning eletriptaanvesinikbromiidi monohüdraati sisaldav farmatseutiline kompositsioon
EE9900112A (et) 2-tsüanoiminoimidasooli derivaadid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
HUP9803040A3 (en) Thiazole derivatives, process for the preparation thereof, use thereof and pharmaceutical compositions containing them
EE200000767A (et) Asendatud triasolopüridasiini derivaat, selle valmistamismeetod ja kasutamine ning farmatseutiline kompositsioon
EE04346B1 (et) Asoolid, nende valmistamismeetod, kasutamine ja farmatseutiline kompositsioon
EE200000099A (et) Antimükootiline kompositsioon, selle kasutamine ja valmistamismeetod ning antimükootiline toode
EE05168B1 (et) N-guanidinoalklamiid, meetod selle valmistamiseks, seda sisaldav farmatseutiline preparaat ning raviotstarbeline kasutamine
EE04902B1 (et) Mikrograanul, selle valmistamismeetod ja farmatseutiline preparaat
EE03996B1 (et) Farmatseutilised kompositsioonid, nende valmistamismeetod ja kasutamine
EE200200109A (et) Asendatud 3-fenüül-5-alkoksü-1,3,4-oksdiasool-2-oon, selle valmistamine ja kasutamine lipaasi inhibiitorina ning seda sisaldav ravim

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

MM4A Lapsed by not paying the annual fees

Effective date: 20081101